Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025 OSLO, Norway, June 18, 2026 /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting...
Hence then, the article about oncoinvent achieves 50 recruitment milestone in phase 2 ovarian cancer study of radspherin was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin® )
Also on site :
- Melania Trump’s Advisor Shades Tom Cruise’s ‘Digger’ After Box Office Bomb — Even Though ‘Melania’ Doc Also Flopped in Theaters
- ‘Chicago Med’ Boss Teases Explosive Hospital Power Struggle and Unrequited Love Coming in Season 12 (Exclusive)
- The Hunting Wives Renewed For Season 3 Ahead Of Season 2 Premiere On Netflix